Cargando…
Muscarinic Receptor Signaling in Colon Cancer
According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fe...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756399/ https://www.ncbi.nlm.nih.gov/pubmed/24212649 http://dx.doi.org/10.3390/cancers3010971 |
_version_ | 1782282089484255232 |
---|---|
author | von Rosenvinge, Erik C. Raufman, Jean-Pierre |
author_facet | von Rosenvinge, Erik C. Raufman, Jean-Pierre |
author_sort | von Rosenvinge, Erik C. |
collection | PubMed |
description | According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fecal bile acids promote colon dysplasia. Conversely, in rodents and in persons with inflammatory bowel disease, low-dose ursodeoxycholic acid treatment alters fecal bile acid composition and attenuates colon neoplasia. In the course of elucidating the mechanism underlying these actions, we discovered that bile acids interact functionally with intestinal muscarinic receptors. The present communication reviews muscarinic receptor expression in normal and neoplastic colon epithelium, the role of autocrine signaling following synthesis and release of acetylcholine from colon cancer cells, post-muscarinic receptor signaling including the role of transactivation of epidermal growth factor receptors and activation of the ERK and PI3K/AKT signaling pathways, the structural biology and metabolism of bile acids and evidence for functional interaction of bile acids with muscarinic receptors on human colon cancer cells. In murine colon cancer models, deficiency of subtype 3 muscarinic receptors attenuates intestinal neoplasia; a proof-of-concept supporting muscarinic receptor signaling as a therapeutic target for colon cancer. |
format | Online Article Text |
id | pubmed-3756399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37563992013-09-04 Muscarinic Receptor Signaling in Colon Cancer von Rosenvinge, Erik C. Raufman, Jean-Pierre Cancers (Basel) Review According to the adenoma-carcinoma sequence, colon cancer results from accumulating somatic gene mutations; environmental growth factors accelerate and augment this process. For example, diets rich in meat and fat increase fecal bile acids and colon cancer risk. In rodent cancer models, increased fecal bile acids promote colon dysplasia. Conversely, in rodents and in persons with inflammatory bowel disease, low-dose ursodeoxycholic acid treatment alters fecal bile acid composition and attenuates colon neoplasia. In the course of elucidating the mechanism underlying these actions, we discovered that bile acids interact functionally with intestinal muscarinic receptors. The present communication reviews muscarinic receptor expression in normal and neoplastic colon epithelium, the role of autocrine signaling following synthesis and release of acetylcholine from colon cancer cells, post-muscarinic receptor signaling including the role of transactivation of epidermal growth factor receptors and activation of the ERK and PI3K/AKT signaling pathways, the structural biology and metabolism of bile acids and evidence for functional interaction of bile acids with muscarinic receptors on human colon cancer cells. In murine colon cancer models, deficiency of subtype 3 muscarinic receptors attenuates intestinal neoplasia; a proof-of-concept supporting muscarinic receptor signaling as a therapeutic target for colon cancer. Molecular Diversity Preservation International (MDPI) 2011-03-02 /pmc/articles/PMC3756399/ /pubmed/24212649 http://dx.doi.org/10.3390/cancers3010971 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review von Rosenvinge, Erik C. Raufman, Jean-Pierre Muscarinic Receptor Signaling in Colon Cancer |
title | Muscarinic Receptor Signaling in Colon Cancer |
title_full | Muscarinic Receptor Signaling in Colon Cancer |
title_fullStr | Muscarinic Receptor Signaling in Colon Cancer |
title_full_unstemmed | Muscarinic Receptor Signaling in Colon Cancer |
title_short | Muscarinic Receptor Signaling in Colon Cancer |
title_sort | muscarinic receptor signaling in colon cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756399/ https://www.ncbi.nlm.nih.gov/pubmed/24212649 http://dx.doi.org/10.3390/cancers3010971 |
work_keys_str_mv | AT vonrosenvingeerikc muscarinicreceptorsignalingincoloncancer AT raufmanjeanpierre muscarinicreceptorsignalingincoloncancer |